Table 3 PPVs for toxic liver disease, hepatic failure without and with toxic liver disease with hepatic necrosis, and jaundice
Evaluable patients N | Confirmed diagnosis (true positive) N | Non-confirmed diagnosis (false positives) N | PPV (95% CI) | |
|---|---|---|---|---|
Toxic liver disease | 26 | 14 | 12 | 53.8% (33.4–73.4%) |
Hepatic failure | ||||
Any hepatic failure | 58 | 36 | 22 | 62.1% (48.4–74.5%) |
Liver synthetic dysfunction | 58 | 31 | 27 | 53.4% (39.9–66.7%) |
Liver synthetic dysfunction with ascites | 58 | 18 | 40 | 31.0% (19.5–44.5%) |
International definition of hepatic failure | 58 | 21 | 37 | 36.2% (24.0–49.9%) |
Hepatic failure including toxic liver disease with hepatic necrosisa | ||||
Any hepatic failure | 61 | 37 | 24 | 60.7% (47.3–72.9%) |
Liver synthetic dysfunction | 61 | 32 | 29 | 52.5% (39.3–65.4%) |
Liver synthetic dysfunction with ascites | 61 | 19 | 42 | 31.1% (19.9–44.3%) |
International definition of hepatic failure | 61 | 21 | 40 | 34.4% (22.7–47.7%) |
Jaundice | 31 | 30 | 1 | 96.8% (83.3–99.9%) |